Stock comparison
Genmab A/S
Iovance Biotherapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
IOVA
Iovance Biotherapeutics
Market cap
$1.47B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | IOVA | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 24F | GMAB |
| Benjamin Graham | 64C | 41D | GMAB |
| Philip Fisher | 48D | 39D | GMAB |
| Peter Lynch | 25F | 3F | GMAB |
| Joel Greenblatt | 76B | 2F | GMAB |
| Charlie Munger | 68C | 28F | GMAB |
| Terry Smith | 71C | 33F | GMAB |
Side-by-side metrics
| Metric | GMAB | IOVA |
|---|---|---|
| Market cap | $16.5B | $1.47B |
| P/E (TTM) | 6.2x | - |
| EV/EBIT | 12.0x | - |
| ROIC (TTM) | 43.78% | -45.33% |
| Gross margin | 93.88% | 114.51% |
| Net margin | 18.23% | -123.9% |
| Revenue CAGR 5y | -18.45% | - |
| EPS CAGR 5y | -23.48% | - |
| Debt / Equity | 0.1x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- ROIC (TTM)43.78%vs -45.33%+197%
- Net margin18.23%vs -123.9%+115%
- Market cap$16.5Bvs $1.47B+91%
IOVA leads on
- P/E (TTM)-vs 6.2x+164%
- EV/EBIT-vs 12.0x+121%
- Gross margin114.51%vs 93.88%+18%
- Debt / Equity0.1xvs 0.1x+12%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.